Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-1480 vs Pembrolizumab in First-Line Advanced Squamous NSCLC
NCT07756645Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Sep 2026
- Primary completion
- Dec 2029
- Countries
- 2
01
Overview
A Phase 3 trial of RC148 in squamous cell carcinoma of the lung (SCCL), sponsored by AbbVie Inc.. Started Sep 2026; status: recruiting.
02
Drugs
RC148
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT07756645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07756645.